Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma Ltd. (IL:CANF)
:CANF
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range0.00 - 8,100.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪18.81M
Enterprise Value11.69B
Total Cash (Recent Filing)₪6.46M
Total Debt (Recent Filing)₪90.00K
Price to Earnings (P/E)―
Beta-0.67
Next Earnings
Mar 26, 2026EPS Estimate
-90Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-86.55
Shares Outstanding2,618,424
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio108.01
Price to Book (P/B)6.26K
Price to Sales (P/S)50509.82
P/FCF Ratio-4.45K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipsStrategic partnerships and collaborations provide a sustainable revenue stream and enhance the company's ability to advance its clinical trials, supporting long-term growth and innovation.
Low Debt LevelsLow debt levels provide financial flexibility and reduce the risk of financial distress, allowing the company to focus resources on R&D and strategic initiatives.
Clinical Trial ProgressProgress in clinical trials, such as achieving enrollment milestones, indicates advancement in the drug development pipeline, potentially leading to future revenue opportunities and market expansion.
Bears Say
Declining RevenuesDeclining revenues suggest challenges in maintaining market demand or competitive pressures, impacting the company's ability to sustain operations and fund R&D activities.
Negative Profit MarginsSeverely negative profit margins highlight operational inefficiencies and financial strain, limiting the company's ability to reinvest in growth and innovation.
Cash Flow ChallengesPersistent negative cash flow indicates ongoing operational inefficiencies, which can hinder the company's ability to fund its R&D pipeline and sustain long-term growth.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 0.00 and its highest was 8100.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪18.81M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 24 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Nov 21, 2025. The company reported -86.547 earnings per share for the quarter, beating the consensus estimate of -438.694 by 352.147.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -90.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 2,618,424 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -86.547 in its last earnings report, beating expectations of -438.694. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.